Answer
Potentially fatal differentiation syndrome associated with injectable azacitidine can involve respiratory distress, pulmonary infiltrates, fever, rash, pulmonary or peripheral oedema, rapid weight gain, pleural or pericardial effusions, hypotension and renal dysfunction.
Sources for this answer
- Vidaza 25 mg/ml powder for suspension for injectionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 25Document updated
Sources checked